192 related articles for article (PubMed ID: 23908346)
41. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
42. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
[TBL] [Abstract][Full Text] [Related]
43. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Fleitas T; Martínez-Sales V; Vila V; Reganon E; Mesado D; Martín M; Gómez-Codina J; Montalar J; Reynés G
Clin Transl Oncol; 2013 Nov; 15(11):897-902. PubMed ID: 23463593
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Correale P; Botta C; Basile A; Pagliuchi M; Licchetta A; Martellucci I; Bestoso E; Apollinari S; Addeo R; Misso G; Romano O; Abbruzzese A; Lamberti M; Luzzi L; Gotti G; Rotundo MS; Caraglia M; Tagliaferri P
Cancer Biol Ther; 2011 Jul; 12(2):112-8. PubMed ID: 21525780
[TBL] [Abstract][Full Text] [Related]
45. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
46. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival.
Sirohi B; Ashley S; Norton A; Popat S; Hughes S; Papadopoulos P; Priest K; O'Brien M
J Thorac Oncol; 2007 Aug; 2(8):735-40. PubMed ID: 17762340
[TBL] [Abstract][Full Text] [Related]
47. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P; Remondo C; Carbone SF; Ricci V; Migali C; Martellucci I; Licchetta A; Addeo R; Volterrani L; Gotti G; Rotundo MS; Tassone P; Sperlongano P; Abbruzzese A; Caraglia M; Tagliaferri P; Francini G
Cancer Biol Ther; 2010 May; 9(9):685-93. PubMed ID: 20697196
[TBL] [Abstract][Full Text] [Related]
48. [Multi-slice spiral CT pulmonary perfusion imaging and the expression of VEGF/PCNA in non-small cell lung cancer].
Liu J; Xiong Z; Zhou H; Zhou M; Zhou J; Fu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 May; 34(5):406-11. PubMed ID: 19483288
[TBL] [Abstract][Full Text] [Related]
49. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
50. Thorax perfusion CT in non-small cell lung cancer.
Ovali GY; Sakar A; Göktan C; Celik P; Yorgancioğlu A; Nese N; Pabuscu Y
Comput Med Imaging Graph; 2007 Dec; 31(8):686-91. PubMed ID: 17904334
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
52. Whole tumour perfusion of peripheral lung carcinoma: evaluation with first-pass CT perfusion imaging at 64-detector row CT.
Li Y; Yang ZG; Chen TW; Deng YP; Yu JQ; Li ZL
Clin Radiol; 2008 Jun; 63(6):629-35. PubMed ID: 18455553
[TBL] [Abstract][Full Text] [Related]
53. Whole-tumor perfusion CT using texture analysis in unresectable stage IIIA/B non-small cell lung cancer treated with recombinant human endostatin.
Shi L; Zhou XL; Sun JJ; Huang JH; Wang X; Li K; Pang PP; Xu YJ; Chen M; Zhang MM
Quant Imaging Med Surg; 2019 Jun; 9(6):968-975. PubMed ID: 31367551
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
55. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
56. Perfusion computed tomography in predicting treatment response of advanced esophageal squamous cell carcinomas.
Li MH; Shang DP; Chen C; Xu L; Huang Y; Kong L; Yu JM
Asian Pac J Cancer Prev; 2015; 16(2):797-802. PubMed ID: 25684528
[TBL] [Abstract][Full Text] [Related]
57. [CT evaluation of response to chemotherapy and/or radiotherapy in primary lung cancer: comparison of response evaluation criteria in solid tumors (RECIST) and the WHO criteria, and comparison of both methods with the histological evaluation].
Konishi K; Kuriyama K; Chino S; Isohashi K; Murata M; Tsuda K; Mitani T; Maeda M; Kadota T; Arisawa J
Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Jan; 64(1):41-5. PubMed ID: 14994510
[TBL] [Abstract][Full Text] [Related]
58. CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology.
Jia Y; Xiao X; Sun Q; Jiang H
Clin Radiol; 2018 Dec; 73(12):1033-1040. PubMed ID: 30115364
[TBL] [Abstract][Full Text] [Related]
59. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
60. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
